IR Information
Interim Report
Initiation of an Arbitration against The Medicines Company Convocation
Notice Concerning Non-operating Income Convocation
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated) Convocation
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting Convocation
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes Convocation
Notice of Revision to the Earnings Forecast for FY2017 Convocation
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Convocation
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma Convocation
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM Convocation
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment Convocation
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice Concerning Non-operating Income Convocation
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated) Convocation
Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies" Convocation
Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes Convocation
SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees Convocation
Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers Convocation
Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates Convocation
Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment Convocation
SymBio's Mid-Range Plan: FY2017 to FY2019 Convocation
Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated) Convocation
Notice Concerning Non-Operating Income Convocation
Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule Convocation
Japan Launch of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg Convocation
Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Convocation
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting Convocation
Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting Convocation
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice concerning Non-operating Expenses Convocation
Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders Convocation
Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg Convocation
Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes Convocation
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting Convocation
Notice concerning Partial Amendment to the Articles of Incorporation Convocation
Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia Convocation
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS) Convocation
Announcement on Achievement of a Sales Milestone for Bendamustine, an Anticancer Agent, in Taiwan, and Receipt of a Milestone Payment related thereto Convocation
Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting Convocation
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501" Convocation
Notice concerning the Change of Major Shareholder Convocation
Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting Convocation
Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting Convocation
Notice concerning the Change of Major Shareholder Convocation
Notice concerning the Change of Major Shareholder Convocation
Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor Convocation
Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders Convocation
SymBio Announces Incorporation of its U.S. Subsidiary Convocation
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting Convocation
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated) Convocation
Notice Concerning Non-operating Expenses Convocation
Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment Convocation
(Correction) Notice concerning partial correction to the "Notice of Appointment of Directors" Convocation
Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees Convocation
Notice of Appointment of Directors Convocation
Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates Convocation
Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS Convocation
SymBio's Long Range Plan: FY2016 to FY2018 Convocation
Notice Concerning Non-operating Expenses Convocation
SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule Convocation
Assessment Status of Bendamustine in Europe Convocation
SymBio starts Global Phase 3 Trial for IV Rigosertib Convocation
SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL Convocation
SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication) Convocation
SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength) Convocation
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients Convocation
Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib Convocation
Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS Convocation
SymBio Partner Announces European Approval of IONSYS® Convocation
Notice Concerning Non-operating Expenses Convocation
Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS Convocation
Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia Convocation
SymBio to Participate in Global Phase 3 Trial for IV Rigosertib Convocation
SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan. Convocation
Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS Convocation
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients Convocation
Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS Convocation
Notice Concerning Non-operating income Convocation
Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS Convocation
Notice Concerning Non-operating Expense Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees Convocation
Notice of Director and Auditor Appointments Convocation
Notice Concerning Change in Status of Major shareholder Convocation
Notice of Nomination of Director Candidates and Auditor Candidates Convocation
SymBio's Long Range Plan: FY2015 to FY2017 Convocation
Notice Concerning Non-Operating Income Convocation
Establishment of Sponsored ADR (American Depositary Receipt) Program Convocation
SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program Convocation
Notice of Revision of the Long Range Plan: FY2014 to FY2016 Convocation
SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version) Convocation
Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment Convocation
Notice of Revision of the Financial Forecast for FY2014 Convocation
Notice Concerning Non-Operation Income Convocation
Notice Concerning Change in Status of Major shareholder Convocation
Notice Concerning Relocation of Head Office Convocation
Notice Concerning Non-Operation Expense Convocation
SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501) Convocation
Notice Concerning Non-Operation Expense Convocation
Notice Concerning Adjustment to Exercise Price of Stock Option Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors Convocation
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees Convocation
Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders Convocation
Notice Concerning the Appointment of Directors Convocation
Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors Convocation
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors Convocation